Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Have Never Been This Bullish On Ra Pharmaceuticals, Inc. (RARX)

During the fourth quarter the Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by nearly 7 percentage points as investors worried over the possible ramifications of rising interest rates. The hedge funds and institutional investors we track typically invest more in smaller-cap stocks than an average investor (i.e. only 298 S&P 500 constituents were among the 500 most popular stocks among hedge funds), and we have seen data that shows those funds paring back their overall exposure. Those funds cutting positions in small-caps is one reason why volatility has increased. In the following paragraphs, we take a closer look at what hedge funds and prominent investors think of Ra Pharmaceuticals, Inc. (NASDAQ:RARX) and see how the stock is affected by the recent hedge fund activity.

Is Ra Pharmaceuticals, Inc. (NASDAQ:RARX) a buy right now? The smart money is in a bullish mood. The number of bullish hedge fund bets inched up by 2 in recent months. Our calculations also showed that RARX isn’t among the 30 most popular stocks among hedge funds.

Hedge funds’ reputation as shrewd investors has been tarnished in the last decade as their hedged returns couldn’t keep up with the unhedged returns of the market indices. Our research has shown that hedge funds’ large-cap stock picks indeed failed to beat the market between 1999 and 2016. However, we were able to identify in advance a select group of hedge fund holdings that outperformed the market by 32 percentage points since May 2014 through March 12, 2019 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that’ll significantly underperform the market. We have been tracking and sharing the list of these stocks since February 2017 and they lost 27.5% through March 12, 2019. That’s why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to.

Felix Baker - Baker Bros.

We’re going to review the key hedge fund action regarding Ra Pharmaceuticals, Inc. (NASDAQ:RARX).

How are hedge funds trading Ra Pharmaceuticals, Inc. (NASDAQ:RARX)?

At Q4’s end, a total of 17 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of 13% from one quarter earlier. The graph below displays the number of hedge funds with bullish position in RARX over the last 14 quarters. So, let’s see which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

RARX_may2019

The largest stake in Ra Pharmaceuticals, Inc. (NASDAQ:RARX) was held by RA Capital Management, which reported holding $34 million worth of stock at the end of December. It was followed by Deerfield Management with a $27.3 million position. Other investors bullish on the company included Citadel Investment Group, Baker Bros. Advisors, and Sectoral Asset Management.

Now, some big names have been driving this bullishness. Cormorant Asset Management, managed by Bihua Chen, established the biggest position in Ra Pharmaceuticals, Inc. (NASDAQ:RARX). Cormorant Asset Management had $8 million invested in the company at the end of the quarter. Noam Gottesman’s GLG Partners also made a $3.8 million investment in the stock during the quarter. The other funds with new positions in the stock are Phill Gross and Robert Atchinson’s Adage Capital Management and Cliff Asness’s AQR Capital Management.

Let’s now review hedge fund activity in other stocks – not necessarily in the same industry as Ra Pharmaceuticals, Inc. (NASDAQ:RARX) but similarly valued. These stocks are Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), Exela Technologies, Inc. (NASDAQ:XELA), WideOpenWest, Inc. (NYSE:WOW), and Himax Technologies, Inc. (NASDAQ:HIMX). This group of stocks’ market caps are closest to RARX’s market cap.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
RCKT 14 176165 -2
XELA 13 102031 -1
WOW 13 35063 2
HIMX 9 28168 -1
Average 12.25 85357 -0.5

View table here if you experience formatting issues.

As you can see these stocks had an average of 12.25 hedge funds with bullish positions and the average amount invested in these stocks was $85 million. That figure was $159 million in RARX’s case. Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is the most popular stock in this table. On the other hand Himax Technologies, Inc. (NASDAQ:HIMX) is the least popular one with only 9 bullish hedge fund positions. Compared to these stocks Ra Pharmaceuticals, Inc. (NASDAQ:RARX) is more popular among hedge funds. Our calculations showed that top 15 most popular stocks) among hedge funds returned 24.2% through April 22nd and outperformed the S&P 500 ETF (SPY) by more than 7 percentage points. Hedge funds were also right about betting on RARX, though not to the same extent, as the stock returned 16.8% and outperformed the market as well.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...